Key Highlights

  • Noxopharm shares were up 10.00% at $0.055 during the 22 October 2026 trading session.
  • CSL research presented at a Washington DC influenza conference tested Noxopharm oligonucleotides with self-amplifying mRNA vaccines.
  • The lead asset, SOF-SKN, is a topical therapy initially being developed for cutaneous lupus erythematosus, with Phase I completed.

Noxopharm Limited (ASX:NOX) shares were up 10.00% at $0.055 during the Trading session on 22 October 2026, at 11:55 am. At the same time the S&P/ASX 200 stood at 8,774.90, down 0.64% (56.40 points), while the All Ordinaries stood at 8,897.80, down 0.66%. Noxopharm is an Australian clinical-stage biotechnology company developing targeted therapies for inflammation, autoimmune diseases and cancer from its Sofra platform.

About the Company

Noxopharm Limited is an Australian clinical-stage biotechnology company listed on the Australian Securities Exchange under the code NOX. Its address is Suite 71, 159 Ridgecrop Drive, Castle Hill, New South Wales. Dr Olivier Laczka is the Chief Executive Officer.

The company develops novel, targeted therapies for inflammation, autoimmune diseases and cancer. It states that its Sofra platform grew out of a discovery in innate immunology and is designed to regulate innate immune signalling with greater precision.

Business Overview

Sofra is based on synthetic nucleic acids known as oligonucleotides, which mimic natural regulators of the body's defence system. The company says this allows selective and modular tuning of immune sensors, either reducing or stimulating their biological responses. Target areas include rheumatoid arthritis, lupus and diabetes, as well as immuno-oncology.

The lead clinical asset is SOF-SKN, a topical therapy initially being developed for cutaneous lupus erythematosus, with Phase I completed and further clinical development progressing. The platform also supports internal and externally collaborated programs across inflammatory and autoimmune diseases, RNA therapeutics and oncology. Noxopharm cites a global autoimmune therapeutics market of US$163.2 billion in 2024 and an immuno-oncology market of US$43 billion in 2023.

CSL Data Presented at the Options XIII Conference

In its announcement dated 1 September 2026, issued from Sydney, Noxopharm said data involving its technology had been presented at the International Society for Respiratory Viruses conference, Options for the Control of Influenza XIII, in Washington DC. The research was conducted by global biopharma company CSL and examined whether oligonucleotides from the Sofra platform could reduce the reactogenicity of self-amplifying mRNA, or sa-mRNA, vaccines.

The company noted that sa-mRNA offers greater dose efficiency and more durable immunity than conventional mRNA vaccines, though the reactogenicity profile of the two platforms is comparable. Noxopharm's anti-inflammatory oligonucleotides were co-delivered with sa-mRNAs, intended to decrease the immune activation that potentially contributes to adverse reactions after vaccination with investigational influenza sa-mRNA vaccines.

What the Poster Reported

The scientific poster stated that the oligonucleotides reduced vaccine-related inflammation markers, supporting their potential to improve Vaccine tolerability. A graph from the poster showed that production of interferon, an inflammatory signalling protein, induced by the sa-mRNA vaccine was greatly reduced by the Noxopharm oligonucleotide, even at doses as low as one nanogram. The figure used blood cells from three human donors and an sa-mRNA H1N1 formulation.

Noxopharm described the conference as the largest global scientific meeting focused on influenza prevention, control and treatment, with speakers from institutions including Johns Hopkins University, Princeton University, the Massachusetts Institute of Technology, the World Health Organization and the US Centers for Disease Control and Prevention.

Related Sector Context

Messenger RNA vaccines and RNA-based therapies form a research-intensive segment of biotechnology, where developers examine ways to reduce adverse reactions and improve tolerability alongside efficacy. Early laboratory findings of the type presented here are generally an initial stage before any clinical evaluation.

Clinical-stage biotechnology shares are often influenced by company-specific developments. At 11:55 am on 22 October 2026 the S&P/ASX 200 was down 0.64% and the All Ordinaries was down 0.66%, while Noxopharm shares were up 10.00% at $0.055 during the session.

Risks to Weigh In

The data come from research carried out by CSL using blood cells from three human donors, which is an early-stage experimental setting. The announcement does not describe any clinical trial of the oligonucleotides with sa-mRNA vaccines, nor any agreement with CSL or another party covering their use.

Noxopharm's lead program, SOF-SKN, has completed Phase I only, and further clinical development carries the usual uncertainties of trial outcomes, regulatory review and funding. The company's forward-looking statements note that actual results may differ materially from those expressed, and the market projections it cites are forecasts to 2033 and 2035.

Catalysts on Watch

The announcement does not set dates for specific events. Chief Executive Dr Laczka said the company will continue to pursue and develop external partnerships where they make strategic sense, and expects its Sofra platform to keep generating interest.

Items to follow include progress in SOF-SKN's continuing clinical development, any Partnership announcements involving the Sofra platform, and further data from collaborators using Noxopharm's oligonucleotides in vaccine or drug research.

Putting It Together

Noxopharm shares were trading higher at $0.055 during the 22 October 2026 session while both benchmark indexes were lower. The company's announcement dated 1 September 2026 reports CSL research on its Sofra oligonucleotides in sa-mRNA vaccine experiments, while its clinical program continues to centre on SOF-SKN.